<div id="readability-page-1"><p>Immunic (NASDAQ:IMUX - Get Free Report) will likely be posting its  Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.1022) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.</p><h2>Immunic Stock Down 4.4%</h2><p>Shares of Immunic stock opened at $0.88 on Thursday. The firm has a market cap of $105.51 million, a price-to-earnings ratio of -1.06 and a beta of 1.58. The business has a 50-day moving average price of $0.65 and a 200-day moving average price of $0.76. Immunic has a twelve month low of $0.51 and a twelve month high of $1.39. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Nantahala Capital Management LLC acquired a new stake in shares of  Immunic in the fourth quarter valued at about $2,337,000.  Millennium Management LLC lifted its stake in  Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company's stock worth $1,825,000 after acquiring an additional 2,888,829 shares in the last quarter.  Laurion Capital Management LP lifted its holdings in  Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company's stock worth $2,072,000 after buying an additional 2,000,000 shares in the last quarter.  Marshall Wace LLP boosted its holdings in  Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company's stock valued at $541,000 after purchasing an additional 486,468 shares during the period.  Finally, Squarepoint Ops LLC purchased a new position in  Immunic in the third quarter worth approximately $239,000. 51.82% of the stock is owned by hedge funds and other institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>IMUX has been the subject of a number of recent research reports. D. Boral Capital cut their target price on shares of Immunic from $8.00 to $4.00 and set a &#34;buy&#34; rating for the company in a report on Friday, February 13th. Roth Mkm assumed coverage on shares of Immunic in a research note on Friday, November 7th. They issued a &#34;buy&#34; rating and a $3.00 target price on the stock. Brookline Capital Acquisition raised shares of Immunic to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 3rd. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of Immunic in a research report on Monday, February 9th. Finally, Chardan Capital raised shares of Immunic to a &#34;strong-buy&#34; rating in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned  a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat.com, Immunic presently has an average rating of &#34;Buy&#34; and a consensus price target of $6.60.</p><p><b>Check Out Our Latest Report on IMUX</b></p><h2>About Immunic</h2> (Get Free Report)<p>Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.  </p><p>Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Immunic</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Immunic Right Now?</h2><p>Before you consider Immunic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.</p><p>While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Immunic (NASDAQ:IMUX) is set to release its Q4 2025 earnings on February 26, with analysts predicting a loss of $0.1022 per share. The stock is currently down 4.4%, trading at $0.88, with a market cap of $105.51 million. Recent institutional activity includes significant stakes acquired by Nantahala Capital Management and Millennium Management. Analysts have mixed ratings on the stock, with a consensus price target of $6.60. Immunic focuses on developing therapies for chronic inflammatory diseases and cancers, with its lead product in Phase 2 clinical development.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares US Pharma

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Immunic

Health Care Select Sector SPDR

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday